Literature DB >> 1713903

Zinc plasma levels in prostatic carcinoma and BPH.

M Lekili1, A Ergen, I Celebi.   

Abstract

Zinc in serum from patients with prostatic carcinoma and BPH before and after treatment was analyzed by atomic absorption spectrometry. There were significant differences between prostatic cancer and BPH. We also found distinct differences in the plasma content of zinc in patients with prostatic carcinoma before and after therapy. We conclude that the zinc concentration in serum may be a valuable index for the differential diagnosis and therapy of prostatic carcinoma.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1713903     DOI： 10.1007/bf02549712

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  7 in total

1.  The distribution of zinc within the human prostate.

Authors:  W K KERR; A G KERESTECI; H MAYOH
Journal:  Cancer       Date:  1960 May-Jun       Impact factor: 6.860

2.  Correlation of prostatic blood flow with 65-zinc activity in intact, castrated and testosterone-treated baboons.

Authors:  R Schoonees; J N de Klerk; G P Murphy
Journal:  Invest Urol       Date:  1969-03

3.  The zinc and copper content of blood leucocytes and plasma from patients with benign and malignant prostates.

Authors:  F K Habib; T C Dembinski; S R Stitch
Journal:  Clin Chim Acta       Date:  1980-07-01       Impact factor: 3.786

4.  Plasma zinc legels in prostatic disease.

Authors:  E G Willden; M R Robinson
Journal:  Br J Urol       Date:  1975-06

5.  Zinc and cadmium plasma and erythrocyte levels in prostatic carcinoma, BPH, urological malignancies, and inflammations.

Authors:  A Feustel; R Wennrich
Journal:  Prostate       Date:  1986       Impact factor: 4.104

6.  Serum copper and zinc levels in melanoma patients.

Authors:  G L Fisher; L E Spitler; K L McNeill; L S Rosenblatt
Journal:  Cancer       Date:  1981-04-01       Impact factor: 6.860

7.  Zinc in human malignancies.

Authors:  P K Chakravarty; A Ghosh; J R Chowdhury
Journal:  Neoplasma       Date:  1986       Impact factor: 2.575
  7 in total
  5 in total

1.  Evidence that Human Prostate Cancer is a ZIP1-Deficient Malignancy that could be Effectively Treated with a Zinc Ionophore (Clioquinol) Approach.

Authors:  Leslie C Costello; Renty B Franklin; Jing Zou; Michael J Naslund
Journal:  Chemotherapy (Los Angel)       Date:  2015-06

2.  Proceedings of the 10th Asian Pacific Congress of Clinical Biochemistry in conjunction with the Australasian Association of Clinical Biochemists' 42nd Annual Scientific Conference.

Authors: 
Journal:  Clin Biochem Rev       Date:  2004

3.  Trace elements and vitamin E status in Nigerian patients with prostate cancer.

Authors:  O A Adaramoye; O Akinloye; I K Olatunji
Journal:  Afr Health Sci       Date:  2010-03       Impact factor: 0.927

Review 4.  The immunological contribution of NF-κB within the tumor microenvironment: a potential protective role of zinc as an anti-tumor agent.

Authors:  Bin Bao; Archana Thakur; Yiwei Li; Aamir Ahmad; Asfar S Azmi; Sanjeev Banerjee; Dejuan Kong; Shadan Ali; Lawrence G Lum; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2011-11-29

5.  Zinc in the human prostate gland: normal, hyperplastic and cancerous.

Authors:  T V Sviridova; S V Zaichick
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.